| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 American Cyanamid Company, Princeton, NJ 08543-0400
A recombinant mucolytic protein, lysostaphin, was evaluated as a potential intramammary therapeutic for Staphylococcus aureus mastitis in dairy cattle. Lysostaphin, a product of Staphylococcus simulans, enzymatically degrades the cell wall of Staphylococcus aureus and is bactericidal. Thirty Holstein-Freisian dairy cattle in their first lactation were infected with Staphylococcus aureus (Newbould 305, ATCC 29740) in all quarters. Infections were established and monitored for somatic cell counts and Staphylococcus aureus colony-forming units 3 wk prior to subsequent treatment. Infected animals were injected through the teat canal with a single dose of recombinant lysostaphin (dose response 1 to 500 mg) or after three successive p.m. millcings with 100 mg of recombinant lysostaphin in 60 ml of sterile phosphate-buffered saline. Animals were considered cured if the milk remained free of Staphylococcus aureus for a total of 28 milkings after last treatment. Kinetic analysis of immunologically active recombinant lysostaphin demonstrated that a minimum bactericidal concentration was maintained in the milk for up to 36 to 48 h after a single infusion of 100 mg of recombinant lysostaphin. The cure rate of quarters receiving recombinant lysostaphin (100 mg in sterile phosphate-buffered saline, administered over three consecutive p.m. milkings) was 20% compared with 29% for sodium cephapirin in saline and 57% for a commercial antibiotic formulation, respectively. An improved formulation of recombinant lysostaphin may prove to be an effective alternative to antibiotic therapy for bovine mastitis.
Key Words: lysostaphin • therapy • mastitis
Submitted on January 24, 1991
Accepted on June 17, 1991
This article has been cited by other articles:
|
|
 |
|
  O. Oluola, L. Kong, M. Fein, and L. E. Weisman Lysostaphin in Treatment of Neonatal Staphylococcus aureus Infection Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2198 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fan, K. Plaut, A. J. Bramley, J. W. Barlow, S. A. Mischler, and D. E. Kerr Persistency of Adenoviral-Mediated Lysostaphin Expression in Goat Mammary Glands J Dairy Sci, March 1, 2004; 87(3): 602 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Kerr and O. Wellnitz Mammary expression of new genes to combat mastitis J Anim Sci, March 1, 2003; 81(suppl_3): 38 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Fan, K. Plaut, A. J. Bramley, J. W. Barlow, and D. E. Kerr Adenoviral-Mediated Transfer of a Lysostaphin Gene into the Goat Mammary Gland J Dairy Sci, July 1, 2002; 85(7): 1709 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kiri, G. Archer, and M. W. Climo Combinations of Lysostaphin with {beta}-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis Antimicrob. Agents Chemother., June 1, 2002; 46(6): 2017 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Climo, R. L. Patron, B. P. Goldstein, and G. L. Archer Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis Antimicrob. Agents Chemother., June 1, 1998; 42(6): 1355 - 1360. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. P. Ryan, W. J. Meaney, R. P. Ross, and C. Hill Evaluation of Lacticin 3147 and a Teat Seal Containing This Bacteriocin for Inhibition of Mastitis Pathogens Appl. Envir. Microbiol., June 1, 1998; 64(6): 2287 - 2290. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
